Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has been on the progressive move since end of November. On Friday, 
the stock added the next 0.94% to its price, while its traded volume remained high. Though, that’s not the end of the story yet.
To make its chart position even stronger, CPRX started a promotional campaign on Saturday and the result is expected today. The compensation for the alerts is still unknown, though a number of promoters put CPRX on their watchlists to support its stock price.
The latest news by Catalyst came up on Dec 2, when the company announced its new Vice President and CFO and reported that CPRX was to present at he American Epilepsy Society’s 65th Annual Meeting. After this date, no further information on CPRX was released. Though, the up move is still on and it is interesting how far it will go.
At first sight, the company’s unaudited 10-Q report looks good when it’s up to its cash position. However, as of September 30, net loss jumped over $1 million, and the deficit accumulated during the development stage went over $35 million.[BANNER]
CPRX expects the combination of the net proceeds of the recently completed offering and existing cash and investments will provide sufficient resources to complete the company’s currently ongoing or planned clinical trials and studies and to continue operations through the middle of 2013.
Though, Catalyst will likely take several years to obtain the necessary regulatory approvals to commercialize its products in the US. Meaning that the company may need additional financing raised through public or private equity offerings, debt financings, or other means.
However, any sale by CPRX of additional equity or convertible debt securities could result in dilution to the company’s current stockholders.
